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Abstract
Background: Diagnosis of community-acquired pneumonia (CAP) caused by Mycoplasma pneumoniae in adults
and adolescents is hampered by a lack of rapid and standardized tests for detection.
Methods: CAP patients from 12 teaching hospitals were prospectively and consecutively recruited. Basic and
clinical information, throat swabs and paired sera were collected. Mycoplasma pneumoniae was detected by IgG
and IgM antibody tests, fluorescence quantitative polymerase chain reaction (FQ-PCR) and culture. A comparative
study of the diagnostic values of three methods, including sensitivity, specificity, positive and negative predictive
values and positive likelihood ratio (PLR) was conducted. A fourfold or greater increase of IgG antibody titers of
paired sera was set as the diagnostic “gold standard”.
Results: One hundred and twenty-five CAP patients (52.8% males, median age 47 years, range 14–85) were
enrolled. Twenty-seven (21.6%) patients were diagnosed with acute Mycoplasma pneumoniae infections by the
“gold standard”. Specificity values of all three methods were around 90%. An increasing trend of sensitivity, positive
predictive value and PLR was found, with the lowest in IgM testing (7.4%, 28.6% and 1.45), intermediate in FQ-PCR
(40.7%, 50% and 3.63), and highest in culture (55.6%, 75% and 10.9).
Conclusions: In the defined group of patients, there was a good agreement between positive rate of MP
cultivation of throat swabs and acute M. pneumoniae infection (PLR of 10.9). Since the sensitivity is low in all of the
evaluated methods, the logical approach would be to incorporate PCR, culture and serological tests for optimum
diagnosis of acute Mycoplasma pneumoniae infections in adults and adolescents.
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Background
Mycoplasma pneumoniae (M. pneumoniae, MP) is a com-
mon human respiratory tract pathogen that causes 6–30%
of community-acquired pneumonia (CAP) cases in adults
all over the world [1], and especially in China, where the
incidence is 20–30% [2,3]. Since the clinical and laboratory
manifestations do not differentiate between pneumonia
caused by typical or atypical pathogens [4,5], and the
commonly described β-lactams are not effective because
M. pneumoniae lacks a cell wall, adequate laboratory
diagnosis of M. pneumoniae pneumonia is important.
Diagnosis of M. pneumoniae infection in routine clinical
practice has been based on serology, culture and polymer-
ase chain reaction (PCR). Among these, paired sera
showing a fourfold increase in IgG antibody titer has been
considered as a more reliable method for the diagnosis of
current M. pneumoniae infection [6-8]. However, because
of difficulty in obtaining convalescent serum and time
constraints, IgG antibody titer tests of paired sera are an
epidemiological rather than a diagnostic tool. Culture of
this organism is slow [9], and the correlation between cul-
ture and infection is tenuous because of the asymptomatic
infection caused by M. pneumoniae [10,11]. The detection
of IgM antibody titer in acute stage serum and fluorescence
quantitative PCR (FQ-PCR) of throat swabs are faster
techniques, but until now, a direct comparison between
paired sera results and the above three assays, especially
the FQ-PCR kit approved by State Food and Drug
Administration of China, has not been made.
This study is based on the Beijing Network for Adult
Community-Acquired Pneumonia, which consists of 12
teaching hospitals in Beijing. We evaluated the accuracy
of IgM serology, FQ-PCR and culture for early diagnosis
of CAP caused by M. pneumoniae, with a fourfold or




A prospective study was conducted in 12 teaching hospitals
(Beijing Chao-Yang Hospital, Beijing Haidian Hospital,
YanTai Yu Huangding Hospital, Peking University People’s
Hospital, Luhe Teaching Hospital of the Capital Medical
University, WangJing Hospital of China Academy of
Chinese Medical Sciences, Peking Union Medical College
Hospital, China-Japan Friendship Hospital, Beijing
Friendship Hospital, Beijing Pinggu Hospital, Huairou
the First Hospital and Air Force General Hospital, PLA) in
Beijing, China. From October 2010 to September 2011,
adults and adolescent patients (≥ 14 years of age) with
radiographically confirmed CAP were enrolled con-
secutively. M. pneumoniae was detected by the central
laboratory, Clinical Microbiological Laboratory of Beijing
Chao-Yang Hospital. Patients with immunosuppression and
those who had received immunosuppressive therapy were
excluded. In addition, pregnant or lactating mothers,
patients from nursing homes, patients whose onset time
was longer than 7 days or patients who had been admitted
to a hospital longer than 2 days within the last 90 days were
also excluded. Clinical features, including comorbidities
(such as diabetes, heart diseases, cerebral vascular disease,
chronic lung and renal disease) and laboratory data, were
recorded on a data sheet and then entered into a computer
database when patients were enrolled. The study was
approved by the institutional review board in Beijing
Chao-Yang Hospital. Written informed consent was
provided by all adults and the parents of patients aged
less than 18 years.
Microbiological laboratory tests
Throat swabs and first serum samples were obtained on
admission, and convalescent serum samples were obtained
2–4 weeks later. Throat swabs were performed with 2 ml
transport broth medium (CM403, OXOID). Specimens
were stored at −80°C until transportation on ice to the
laboratory within 2 weeks.
For M. pneumoniae culture, throat swab specimens were
vortexed, supplemented with amphotericin B and peni-
cillin, and inoculated into SP-4 medium. The medium
was incubated at 37°C, and observed daily for 2–6 weeks
for a decrease in pH (a red to yellow color change).
Positive cultures were confirmed by PCR assay as previ-
ously reported [12].
DNA was extracted from 200 μl of throat swab sample
by manual nucleic acid extraction (Qiagen QIAmp DNA
Mini Kit, Valencia, CA). M. pneumoniae was detected by a
commercial FQ-PCR kit (Daan Gene, Guangzhou, China)
approved by State Food and Drug Administration, targeting
the 16S ribosomal RNA gene [GenBank:AF132740]. The
FQ-PCR mixture was prepared in a total volume of 45 μl,
containing 3 μl of sample DNA. FQ-PCR was performed
under the following conditions: initial activation at 93°C for
2 min, followed by 10 cycles at 93°C for 45 s and 55°C for
1 min, and 30 cycles at 93°C for 30 s and 45°C for
30 s. The results were displayed as qualitative. An
internal control, targeted human ribonuclease protein
(hRNP) gene, was incorporated. The amplifications were
performed using the AB 7500 Real Time PCR System
(Applied Biosystems, Foster City, CA) according to the
manufacturer’s instructions.
The specimens were quantitatively tested for IgG
and IgM antibodies against M. pneumoniae using the
Virion/Serion ELISA kit (GmbH Germany ESR127G
and ESR127M). Antibody activities were given in U/ml.
Based on the manufacturer’s recommendation, MP IgG
calculation was interpreted as follows: positive results
(> 30 U/ml), borderline results (20–30 U/ml) and
negative results (< 20 U/ml); and for IgM: positive results
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(> 17 U/ml), borderline results (13–17 U/ml), and negative
results (< 13 U/ml). All ELISA reactions were performed
according to the manufacturer’s instructions on the
Thermo Multiskan MK3 (Thermo Fisher Scientific,
Waltham, MA) system by the same technicians.
Microbiological examination was also performed in
throat swab, sputum, urine and blood. The etiology was
considered definite if one of the following criteria was
met: (1) positive bacterial culture; (2) positive urinary
antigen for L pneumophila (Binax Now L pneumophila
urinary antigen test; Trinity Biotech, Bray, Ireland);
(3) positive urinary antigen for S pneumoniae (Binax Now
S pneumonia urinary antigen test; Emergo Europe, The
Netherlands); (4) detection of respiratory viruses by
RT-PCR using a Seeplex RV Detection Kit (Seegene
Biotechnology Inc., Seoul, Korea), including respiratory
syncytial virus A and B, influenza virus (IFV) A and B,
parainfluenza virus (PIV) 1–4, human rhinovirus (HRV),
enterovirus, human coronavirus (229E/NL63 and OC43/
HKU1), human metapneumovirus (hMPV), adenovirus
(AdV), and human bocavirus.
Statistical analysis
Comparisons of clinical characteristics and clinical
outcomes were conducted between patients with M.
pneumoniae positive and negative group, using an unpaired
Student’s t-test, the Mann–Whitney test, or the Chi-square
test (SPSS for Windows 16.0). A p-value < 0.05 was
considered statistically significant. Sensitivity, specificity
and predictive values were determined by standard
procedures. Clinical diagnostic values of different tests
were evaluated by likelihood ratios. Strong evidence to
rule in diagnoses in most circumstances when the positive
likelihood ratio was above 10 [13].
Results
During our 2-year prospective study, 125 CAP patients
with paired sera meeting the inclusion criteria were
enrolled. There were 66 males (52.8%) and 59 females
(47.2%), and the patients’ ages ranged from 14 to 85 years
(median 47 years) (see Table 1). Overall, acute M.
pneumoniae infection was diagnosed in 27/125 (21.6%)
patients showing a fourfold or greater increase in IgG
antibody titer of paired sera. Twenty-three patients had
causative pathogens other than M. pneumoniae. Among
these patients, one was positive for PIV types 1 and 2,
and IFVA; one was positive for IFVA and Pseudomonas
aeruginosa; one was positive for IFVA and Klebsiella
pneumoniae; nine were positive for IFVA; three were
positive for adenovirus; three were positive for PIV type
1; one was positive for hMPV; one was positive for HRV;
one was positive for PIV type 2; and one was positive for
PIV type 3. Patients positive for M. pneumoniae had a
median age of 34 years (range 16–77 years), which was
significantly younger thanM. pneumoniae-negative patients
(54.5; range 14–85) years, p = 0.002). M. pneumoniae infec-
tions were less likely to have comorbidities (p = 0.039).
There was no difference in smoking status between
the two groups. A similar distribution of most symptoms
were found in both groups on admission, with the
exception that the duration of fever before admission
was longer in the group with M. pneumoniae infection
than in the group without (p = 0.013). The group with
M. pneumoniae infection had a higher mean heart rate
(p < 0.001). The two groups had a similar pattern of
biochemical and haematological findings. There was no
difference in use of antibiotics, treatment status or days
after onset of the IgM testing between the two groups.
The results of IgM testing, FQ-PCR and culture were
compared (see Table 2). M. pneumoniae positive rates
evaluated by IgM antibody testing in acute stage serum
(5.6%), FQ-PCR (17.6%) and culture (16%) were lower
than the result of paired sera (21.6%). Among the 27
patients positive for M. pneumoniae, only two (7.4%) were
found to be positive by IgM antibody testing, 11 by FQ-
PCR (40.7%) and 15 by culture (55.6%). For all of the 103
non-M. pneumoniae infections tested by FQ-PCR, hRNP
gene had been successfully amplified (data not shown).
Among the discordant results, eight patients showed a
fourfold or greater increase in IgG titers, but had negative
results in all three methods. Fifteen patients were negative
by paired sera, while positive by other methods. Among
them, four were positive by both FQ-PCR and culture, one
was positive by FQ-PCR and IgM test, one was positive by
culture and IgM test, six were positive by FQ-PCR, and
three were positive by IgM test. When evaluated by the
Japanese Respiratory Society (JRS) scoring system [14], 17
patients positive by paired sera and 40 patients negative
by paired sera scored ≥ 4.
By using paired sera showing a fourfold or greater
increase in IgG antibody titer as the “gold standard”,
diagnostic parameters of the three methods have been
evaluated (see Table 3), including sensitivity, specificity,
positive and negative predictive values (PPV and NPV
respectively) and positive likelihood ratio (PLR). Specificity
and NPV of all three methods were high, around 90% in
specificity and around 80% in NPV. A similarly increasing
trend of sensitivity, PPV and PLR was lowest in IgM anti-
body testing (7.4%, 28.6% and 1.45, respectively), intermedi-
ate in FQ-PCR (40.7%, 50% and 3.63, respectively), and
highest in culture (55.6%, 75% and 10.9, respectively).
Discussion
Our results show that M. pneumoniae is an important
pathogen of adolescent and adult CAP patients, consistent
with the findings of the CAPNETZ report in 2009 [15]. In
the present study, we also demonstrate that, compared with
non-mycoplasma infections, CAP patients infected with M.
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pneumoniae are younger, less likely to have comorbidities,
and have longer duration of fever before admission.
After infection by M. pneumoniae, IgM antibodies
appear during the first week of the illness, and reach peak
titers during the third week. Martínez et al. have found
that the sensitivity of IgM assay was 33.3% in diagnosis of
acute M. pneumoniae infection in adult CAP patients
[16]. In our study, however, the sensitivity of the IgM
assay is only 7.4% compared with a fourfold increase of
IgG titers. In some adult patients, the antibodies are
constantly negative or produced 15 days after onset as
a result of multiple previous infections [17,18]. Therefore,
using the IgM assay as the sole test may provide inadequate
information.
When compared with PCR, the sensitivity of culture
from respiratory specimens has turned out to be as low
as 61.5% [19]. Similarly, She et al. reported that culture was
unacceptably insensitive for diagnosing M. pneumoniae
infection [7]. In our study, however, there was no difference
between the positive rates of the two methods, just as
Waris et al. found in children [20]. Furthermore, the values
of diagnostic parameters, including specificity, sensitivity,
positive and negative predictive values and positive
likelihood ratio, are the highest among the three methods
Table 1 Demographic and Clinical features and laboratory findings of studied patients
All patients MP positive MP negative P value
N = 125 (%) N = 27 (%) N = 98 (%)
Age (years) 47 (14–85) 34 (16–77) 54.5 (14–85) 0.002
Gender (male) 66 (52.8) 13 (48.15) 53 (54.08) 0.665
Comorbidities 30 (24.0) 2 (7.41) 28 (28.57) 0.039
Current smoker 38 (30.4) 6 (22.22) 32 (32.65) 0.57
Symptoms
Fever 110 (88.0) 25 (92.59) 85 (86.73) 0.521
Duration from onset (days) 3 (2–5) 4 (3–5.5) 3 (2–5) 0.013
Tmax (°C) 39.06 ± 0.58 39.22 ± 0.57 39 ± 0.58 0.113
Cough 114 (91.2) 27 (100.00) 87 (88.78) 0.119
Sputum production 83 (66.4) 20 (74.07) 60 (61.22) 0.37
Dyspnea 22 (17.6) 7 (25.93) 15 (15.31) 0.253
Chest pain 17 (13.6) 4 (14.81) 13 (13.27) 0.761
Digestive symptoms 11 (8.8) 5 (18.52) 6 (6.12) 0.052
Heart rate/min 85.36 ± 18.07 96.7 ± 16.71 85.16 ± 11.27 0.000
Respiratory rate/min 22.32 ± 12.38 20 ± 1.78 20.13 ± 2.86 0.819
Laboratory findings
White blood cell (109/L) 8.78 ± 4.16 8.16 ± 3.11 8.94 ± 4.4 0.386
Neutrophil (%) 71.73 ± 12.10 71.11 ± 9.3 71.89 ± 12.8 0.77
Lymphocyte (%) 19.39 ± 9.99 18.5 ± 7.14 19.6 ± 10.64 0.614
Hematocrit (%) 42.15 ± 28.86 39.86 ± 4.7 42.7 ± 32.29 0.659
Hemoglobin (g/L) 132.54 ± 20.72 135.68 ± 16.05 131.71 ± 21.78 0.387
Platelet (109/L) 207.77 ± 68.55 192.77 ± 50.94 211.76 ± 72.21 0.211
ESR (mm/hr) n = 85 41.51 ± 26.14 40.05 ± 26.19 41.92 ± 26.31 0.785
C-reactive protein (mg/L) n = 83 66.78 ± 65.65 63.75 ± 51.97 67.74 ± 69.78 0.841
Antibiotic usage before admission within 1 week 77 (61.6) 18 (66.67) 59 (60.2) 0.657
Site of care (n = 125) 0.667
Outpatient 51 (40.8) 10 (37.04) 41 (41.84)
Hospitalization 74 (59.2) 17 (62.96) 57 (58.16)
Duration of hospitalization (days) 14 (10–18) 13 (6.5-19) 14 (11–18) 0.549
Days after onset at the IgM testing 4 (1–7) 4 (2–7) 3.5 (1–7) 0.246
Note: The data are presented as means ± standard deviations, no./total no. (%), or median (range).
Comparison is conducted between MP positive (n = 27) and negative (n = 98) group.
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evaluated here. In particular, a PLR of 10.9 means that
there is a reasonable correlation between culture results
and true infection. However, the prolonged turnaround
time limits the clinical application of culture.
Compared with serology and culture, PCR (especially
real-time PCR) is more rapid, practicable and sensitive,
and has been suggested to be more suitable for early
diagnosis of acute M. pneumoniae infection [21,22].
Touati et al. have evaluated five commercial kits based
on PCR, and found that the sensitivities of the kits were
62–98% [23]. Similarly, Martínez et al. observed the
sensitivity, specificity, PPV and NPV of the PCR to be
66.7%, 98.5%, 78.3% and 97.3%, respectively [16]. In the
present study, however, the sensitivity, specificity, PPV
and NPV of the FQ-PCR kit targeted to 16 S rRNA gene
were 40.7%, 88.9%, 50% and 84.6%, respectively. The low
sensitivity of PCR testing may be due to the low bacter-
ial load resulting from previous antimicrobial treatment
or dilution of the sample in the throat swabs below the
limit of detection. The detection limit of our FQ-PCR
kit is stated as 10 copies per μl in the manual, which is
lower than 0.1–1 copies per μl that other commercial
kits reported [23,24]. In addition, it was found that the
efficiency of the PCR assay could be influenced by sample
type, and sputum could be superior to other respiratory
samples including throat swab [25].
Possible reasons contributing to discordant results
between FQ-PCR or culture, and IgG serology have been
explored. Four patients (one positive by FQ-PCR and
culture, and three positive by FQ-PCR) might represent
asymptomatic carriage of M. pneumoniae as a result of
persistence from a previous infection, since these patients’
respective CAP etiologies had been identified with IFVA,
hMPV, AdV and HRV. Five patients (three positive by FQ-
PCR and culture, and two positive by FQ-PCR or culture
and IgM test) showed 2.5–3.8 fold increase of IgG response,
which could be explained by an inadequate time interval
(mean interval was 17 days). The remaining three patients
(only positive by FQ-PCR) were 69, 73 and 74 years old.
They failed to develop IgG antibody response in paired
sera, which could be interpreted as a deterioration of the
immune response due to ageing [26]. These cases highlight
the limitations of a serological diagnosis, which could
be affected by the timing of specimen collection and the
age of the patient.
Recently, in China, Yin et al. demonstrated the good
sensitivity and specificity of the JRS scoring system for
the early presumptive diagnosis of M. pneumoniae pneu-
monia [14]. In our cohort, we showed that with a four-
fold or greater increase of IgG antibody titers of paired
sera as the “gold standard”, the sensitivity and specificity
of JRS scoring were 63% and 59.2%, respectively. With
positivity either by PCR, culture, IgM, or a fourfold in-
crease of IgG as the diagnosis for M. pneumoniae pneu-
monia, the sensitivity decreased to 61.9% and specificity
increased to 74.7%.
The limitations of the study included: 1) because of
cost consideration, we evaluated only one FQ-PCR kit
approved by State Food and Drug Administration of
China; and 2) in patients who had received antibiotics,
including macrolides and fluoroquinolones, the positive
rates of culture and FQ-PCR may have been decreased.
Conclusions
In the defined group of patients, there was a good
agreement between positive rate of MP cultivation of throat
swabs and acute M. pneumoniae infection (PLR of 10.9).
Since the sensitivity was low in all evaluated methods, the
logical approach would be to incorporate PCR, culture
and serological tests for optimum diagnosis of acute
M. pneumoniae infections in adults and adolescents.
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